MX2020008096A - Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico. - Google Patents

Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico.

Info

Publication number
MX2020008096A
MX2020008096A MX2020008096A MX2020008096A MX2020008096A MX 2020008096 A MX2020008096 A MX 2020008096A MX 2020008096 A MX2020008096 A MX 2020008096A MX 2020008096 A MX2020008096 A MX 2020008096A MX 2020008096 A MX2020008096 A MX 2020008096A
Authority
MX
Mexico
Prior art keywords
sub
relaxin
therapeutic use
chain peptides
lipidated
Prior art date
Application number
MX2020008096A
Other languages
English (en)
Inventor
Olivier Duclos
Sergio Mallart
Elisabetta Bianchi
Stéphane Illiano
Claire Minoletti-Hochepied
Raffaele Ingenito
Paola Magotti
Alessia Santoprete
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2020008096A publication Critical patent/MX2020008096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un péptido de Relaxina monocatenario biológicamente activo que tiene la siguiente fórmula (I): Nter-Ac-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25 -S-X27-X28-X29-X30-X31-X32-X33-NH2-Cter o una sal o solvato de este. También trata sobre una composición farmacéutica que comprende al menos un péptido de la invención, y el péptido o la composición farmacéutica para su uso como medicamento.
MX2020008096A 2018-01-31 2019-01-30 Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico. MX2020008096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (1)

Publication Number Publication Date
MX2020008096A true MX2020008096A (es) 2020-09-24

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008096A MX2020008096A (es) 2018-01-31 2019-01-30 Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico.

Country Status (18)

Country Link
US (2) US10961295B2 (es)
EP (1) EP3746467A1 (es)
JP (1) JP7295871B2 (es)
KR (1) KR20200116085A (es)
CN (1) CN111770934A (es)
AR (1) AR114325A1 (es)
AU (1) AU2019214358B2 (es)
BR (1) BR112020014834A2 (es)
CA (1) CA3089657A1 (es)
CO (1) CO2020008308A2 (es)
IL (1) IL276170A (es)
MA (1) MA52994A (es)
MX (1) MX2020008096A (es)
PH (1) PH12020551118A1 (es)
SG (1) SG11202006903WA (es)
TW (1) TWI763972B (es)
UY (1) UY38069A (es)
WO (1) WO2019149782A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149782A1 (en) 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
CN116710462A (zh) 2021-01-20 2023-09-05 维京治疗公司 用于治疗代谢病症和肝病的组合物和方法
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348723A (zh) * 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
BR112014000055A2 (pt) * 2011-07-01 2017-06-13 Bayer Ip Gmbh polipeptídeos de fusão de relaxina e usos dos mesmos
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
WO2013017679A1 (en) * 2011-08-04 2013-02-07 Pharis Biotec Gmbh Process for preparing human relaxin-2
US20160152679A1 (en) * 2012-05-24 2016-06-02 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
KR102302634B1 (ko) * 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
CA2945838C (en) * 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
HUE052977T2 (hu) * 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
US10266578B2 (en) * 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149782A1 (en) 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TW201934572A (zh) 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途
CA3145491A1 (en) * 2019-07-31 2021-02-04 Stacey Lynn Lee Relaxin analogs and methods of using the same

Also Published As

Publication number Publication date
WO2019149782A1 (en) 2019-08-08
EP3746467A1 (en) 2020-12-09
CO2020008308A2 (es) 2020-10-30
UY38069A (es) 2019-08-30
US11725036B2 (en) 2023-08-15
CA3089657A1 (en) 2019-08-08
SG11202006903WA (en) 2020-08-28
US20210292387A1 (en) 2021-09-23
AR114325A1 (es) 2020-08-19
TWI763972B (zh) 2022-05-11
RU2020126210A (ru) 2022-02-28
JP2021512099A (ja) 2021-05-13
MA52994A (fr) 2021-05-05
US10961295B2 (en) 2021-03-30
AU2019214358A1 (en) 2020-08-20
PH12020551118A1 (en) 2021-07-05
CN111770934A (zh) 2020-10-13
IL276170A (en) 2020-09-30
TW201940505A (zh) 2019-10-16
JP7295871B2 (ja) 2023-06-21
KR20200116085A (ko) 2020-10-08
BR112020014834A2 (pt) 2020-12-08
US20190233494A1 (en) 2019-08-01
AU2019214358B2 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
MX2020008096A (es) Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico.
WO2020097537A3 (en) Fused ring compounds
MX2020007944A (es) Nanocomplejos similares a los lípidos y sus usos.
PH12019500074A1 (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
MX2021004707A (es) Nuevos compuestos antihelminticos.
MX2021015935A (es) Formas de sal de acido bempedoico y metodos para utilizar el mismo.
HK1088840A1 (en) Stable analogs of glp-1 glp-1
PH12018502465A1 (en) Mic-1 compounds and use thereof
TW200800944A (en) Benzamide compounds
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
PH12020551486A1 (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
SE0302192D0 (sv) Novel compounds
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
CO2022003321A2 (es) Moduladores de sting (estimulador de genes de interferón)
MX2021014680A (es) Derivado de benzotriazol.
CR20200619A (es) Compuestos de cianotriazol y usos de los mismos
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2022005440A (es) Polipeptido con efecto inhibidor de metaloproteasa de matriz 2 (mmp2).
PH12019502852A1 (en) Novel compounds activating the nrf2 pathway
AR122310A1 (es) Moduladores de sting (estimulador de genes de interferón)
MX2021013489A (es) Combinacion farmaceutica que comprende trazodona para el tratamiento del dolor neuropatico.